Clinical Trials Logo

Recurrent Uterine Corpus Carcinoma clinical trials

View clinical trials related to Recurrent Uterine Corpus Carcinoma.

Filter by:

NCT ID: NCT03552471 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Start date: July 12, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back. Drugs such as mirvetuximab soravtansine are antibodies linked to a toxic substance and may help find certain tumor cells and kill them without harming normal cells. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving mirvetuximab soravtansine and rucaparib camsylate may work better in treating participants with recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer.

NCT ID: NCT03508570 Not yet recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Start date: August 2018
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the safest combination dose of nivolumab and ipilimumab that can be given by an intraperitoneal (IP) infusion to patients with gynecologic cancers. An IP infusion is an injection of the study drugs into the abdomen. This is an investigational study. Nivolumab and ipilimumab are both FDA approved and commercially available for the treatment of many different types of cancer. However, they are not FDA-approved for the treatment of gynecological cancers. It is considered investigational to use the combination of ipilimumab and nivolumab in patients with gynecological cancers and to give these drugs by an IP infusion. The study doctor can explain how the study drugs are designed to work. Up to 48 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT03367741 Recruiting - Clinical trials for Recurrent Uterine Corpus Carcinoma

Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer

Start date: January 26, 2018
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well cabozantinib and nivolumab work in treating patients with endometrial that has come back or spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating endometrial cancer.

NCT ID: NCT03348631 Not yet recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer

Start date: July 30, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well tazemetostat works in treating patients with ovarian, primary peritoneal, or endometrial cancer that has come back. Drugs used in chemotherapy, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT03120624 Recruiting - Clinical trials for Ovarian Endometrioid Adenocarcinoma

VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer

Start date: September 15, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells.

NCT ID: NCT02996825 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Start date: October 2, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer that has come back. Monoclonal antibodies, such as mirvetuximab soravtansine, may interfere with the ability of tumor cells to grow and spread. Drugs used in the chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving mirvetuximab soravtansine and gemcitabine may work better in treating patients with FRalpha-positive ovarian, primary peritoneal, fallopian tube, endometrial, or triple negative breast cancer.

NCT ID: NCT02728258 Suspended - Clinical trials for Recurrent Uterine Corpus Carcinoma

Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Start date: September 16, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well copanlisib works in treating patients with endometrial cancer that has not decreased or disappeared, and the cancer may still be in the body despite treatment (persistent) or has come back (recurrent). Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02657928 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer

Start date: July 8, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a period of improvement. Ribociclib may stop the growth of tumor cells by blocking some enzymes needed for cell growth. Cancer cells that are estrogen receptor positive may need estrogen to grow. Letrozole lowers the amount of estrogen made by the body and this may stop the growth of tumor cells that need estrogen to grow. Giving ribociclib together with letrozole may be an effective treatment in patients with ovarian, fallopian tube, primary peritoneal, or endometrial cancer.

NCT ID: NCT02578888 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies

Start date: April 2015
Phase: N/A
Study type: Interventional

This randomized clinical trial studies a palliative care program in improving the quality of life of patients with high-risk gynecologic malignancies that is original or first tumor in the body (primary) or has come back (recurrent). Palliative care is care given to patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual. Studying a palliative care program may help doctors learn more about patients quality of life, use of healthcare services, and the relief of pain.

NCT ID: NCT02465060 Recruiting - Lymphoma Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.